% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Djaleb:277707,
      author       = {L. Djaïleb and W. R. Armstrong and D. Thompson and A.
                      Gafita and A. Farolfi and A. Rajagopal and T. R. Grogan and
                      K. Nguyen and M. R. Benz and M. Hotta and F. Barbato and F.
                      Ceci and S. M. Schwarzenböck and M. Unterrainer and H. D.
                      Zacho and R. Juarez and M. Cooperberg and P. Carroll and S.
                      Washington and R. E. Reiter and M. Eiber and K. Herrmann$^*$
                      and W. P. Fendler$^*$ and J. Czernin and T. A. Hope and J.
                      Calais},
      title        = {{P}resurgical 68{G}a-{PSMA}-11 {P}ositron {E}mission
                      {T}omography for {B}iochemical {R}ecurrence {R}isk
                      {A}ssessment: {A} {F}ollow-up {A}nalysis of a {M}ulticenter
                      {P}rospective {P}hase 3 {I}maging {T}rial.},
      journal      = {European urology},
      volume       = {84},
      number       = {6},
      issn         = {0302-2838},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2023-01424},
      pages        = {588-596},
      year         = {2023},
      note         = {2023 Dec;84(6):588-596},
      abstract     = {In the initial staging of patients with high-risk prostate
                      cancer (PCa), prostate-specific membrane antigen positron
                      emission tomography (PSMA-PET) has been established as a
                      front-line imaging modality. The increasing number of
                      PSMA-PET scans performed in the primary staging setting
                      might be associated with decreases in biochemical recurrence
                      (BCR)-free survival (BCR-FS).To assess the added prognostic
                      value of presurgical PSMA-PET for BCR-FS compared with the
                      presurgical Cancer of the Prostate Risk Assessment (CAPRA)
                      and postsurgical CAPRA-Surgery (CAPRA-S) scores in patients
                      with intermediate- to high-risk PCa treated with radical
                      prostatectomy (RP) and pelvic lymph node dissection.This is
                      a follow-up study of the surgical cohort evaluated in the
                      multicenter prospective phase 3 imaging trial (n = 277;
                      NCT03368547, NCT02611882, and NCT02919111).Each
                      68Ga-PSMA-11-PET scan was read by three blinded independent
                      readers. PSMA-PET prostate uptake (low vs high), PSMA-PET
                      extraprostatic disease (N1/M1), and CAPRA and CAPRA-S scores
                      were used to assess the risk of BCR. Patients were followed
                      after RP by local investigators using electronic medical
                      records. BCR was defined by a prostate-specific antigen
                      (PSA) level increasing to ≥0.2 ng/ml after RP or
                      initiation of PCa-specific secondary treatment (>6 mo after
                      surgery). Univariate and multivariable Cox models, and
                      c-statistic index were performed to assess the prognostic
                      value of PSMA-PET and for a comparison with the CAPRA and
                      CAPRA-S scores.From December 2015 to December 2019, 277
                      patients underwent surgery after PSMA-PET. Clinical
                      follow-up was obtained in 240/277 $(87\%)$ patients. The
                      median follow-up after surgery was 32.4 (interquartile range
                      23.3-42.9) mo. Of 240 BCR events, 91 $(38\%)$ were observed.
                      PSMA-PET N1/M1 was found in 41/240 $(17\%)$ patients.
                      PSMA-PET prostate uptake, PSMA-PET N1/M1, and CAPRA and
                      CAPRA-S scores were significant univariate predictors of
                      BCR. The addition of PSMA-PET N1/M1 status to the
                      presurgical CAPRA score improved the risk assessment for BCR
                      significantly in comparison with the presurgical CAPRA score
                      alone (c-statistic 0.70 [0.64-0.75] vs 0.63 [0.57-0.69]; p <
                      0.001). The C-index of the postsurgical model utilizing the
                      postsurgical CAPRA-S score alone was not significantly
                      different from the presurgical model combining the
                      presurgical CAPRA score and PSMA-PET N1/M1 status (p =
                      0.19).Presurgical PSMA-PET was a strong prognostic biomarker
                      improving BCR-FS risk assessment. Its implementation in the
                      presurgical risk assessment with the CAPRA score improved
                      the performance and reduced the difference with the
                      reference standard (postsurgical CAPRA-S score).The use
                      prostate-specific membrane antigen positron emission
                      tomography improved the assessment of biochemical recurrence
                      risk in patients with intermediate- and high-risk prostate
                      cancer who were treated with radical prostatectomy and
                      pelvic lymph node dissection.},
      keywords     = {Cancer of the Prostate Risk Assessment score (Other) /
                      Cancer of the Prostate Risk Assessment—Surgery score
                      (Other) / Pelvic lymph node dissection (Other) / Prognostic
                      value (Other) / Prostate-specific membrane antigen positron
                      emission tomography (Other) / Radical prostatectomy (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37482512},
      doi          = {10.1016/j.eururo.2023.06.022},
      url          = {https://inrepo02.dkfz.de/record/277707},
}